Polar Capital Holdings Plc Sells 13,670 Shares of LivaNova PLC (NASDAQ:LIVN)

Polar Capital Holdings Plc lowered its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 10.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 112,094 shares of the company's stock after selling 13,670 shares during the quarter. Polar Capital Holdings Plc owned about 0.21% of LivaNova worth $5,191,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its holdings in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock valued at $780,000 after buying an additional 289 shares in the last quarter. Xponance Inc. grew its holdings in LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after buying an additional 445 shares in the last quarter. Mariner LLC grew its holdings in LivaNova by 8.4% during the 4th quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after buying an additional 446 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in LivaNova by 0.6% during the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after buying an additional 667 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $0.83 during midday trading on Wednesday, hitting $44.06. 130,876 shares of the company's stock were exchanged, compared to its average volume of 645,465. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $61.94. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 104.86 and a beta of 0.84. The business's fifty day moving average price is $38.61 and its two-hundred day moving average price is $44.76.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday. Barclays reduced their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Stifel Nicolaus reduced their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Finally, Robert W. Baird lifted their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and an average price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.